Oligonucleotide conjugates for therapeutic applications.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Therapeutic delivery

• Publication date

  2013-07-24

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.4155/tde.13.47PMID 23883124PMCID PMC3787477
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MicroRNAs and cancer

  2014cited by this paper
• Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection

  2013cited by this paper
• Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges

  2013cited by this paper
• Rational design of an immunoconjugate for selective knock-down of leukemia-specific E2A-PBX1 fusion gene expression in human Pre-B leukemia.

  2013cited by this paper
• Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides

  2013cited by this paper
• Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**

  2012cited by this paper
• Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.

  2012cited by this paper
• Co-Injection of a Targeted, Reversibly Masked Endosomolytic Polymer Dramatically Improves the Efficacy of Cholesterol-Conjugated Small Interfering RNAs In Vivo

  2012cited by this paper
• The chemistry and biology of oligonucleotide conjugates.

  2012cited by this paper
• Therapeutic Potential of Mipomersen in the Management of Familial Hypercholesterolaemia

  2012cited by this paper
• Facile double-functionalization of designed ankyrin repeat proteins using click and thiol chemistries.

  2012cited by this paper
• RNA-based therapeutics: current progress and future prospects.

  2012cited by this paper
• Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy.

  2012cited by this paper
• Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2+ Breast Cancer Growth and Metastasis

  2012cited by this paper
• Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides.

  2012cited by this paper
• Exon-skipping drug pulls ahead in muscular dystrophy field

  2012cited by this paper
• Challenges in Development of Targeted Liposomal Therapeutics

  2012cited by this paper
• Click-modified anandamide siRNA enables delivery and gene silencing in neuronal and immune cells.

  2012cited by this paper
• Discovering the first microRNA-targeted drug

  2012cited by this paper
• Defined Folate-PEG-siRNA Conjugates for Receptor-specific Gene Silencing

  2012cited by this paper
• Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system

  2012cited by this paper
• Polymers for siRNA delivery: inspired by viruses to be targeted, dynamic, and precise.

  2012cited by this paper
• Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy

  2012cited by this paper
• Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia

  2012cited by this paper
• Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

  2012cited by this paper
• Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept.

  2012cited by this paper
• Designed ankyrin repeat proteins (DARPins) from research to therapy.

  2012cited by this paper
• Off-Target Effects and Safety Aspects of Phosphorothioate Oligonucleotides

  2012cited by this paper
• Comparing the intracellular fate of components within a noncovalent streptavidin nanoparticle with covalent conjugation.

  2012cited by this paper
• Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes

  2011cited by this paper
• Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides.

  2011cited by this paper
• Systemic administration of PRO051 in Duchenne's muscular dystrophy.

  2011cited by this paper
• DARPins and other repeat protein scaffolds: advances in engineering and applications.

  2011cited by this paper
• Endosomal escape pathways for delivery of biologicals.

  2011cited by this paper
• MicroRNAs and Cancer Therapeutics

  2011cited by this paper
• Antisense drug discovery and development.

  2011cited by this paper
• High-Density Lipoprotein Facilitates In Vivo Delivery of α-Tocopherol–Conjugated Short-Interfering RNA to the Brain

  2011cited by this paper
• Clathrin-independent endocytosis: mechanisms and function.

  2011cited by this paper
• Survival in a phase III, randomized, double-blind study of dacarbazine with or without oblimersen (Bcl-2 antisense) in patients with advanced melanoma and low-normal serum lactate dehydrogenase (LDH; AGENDA).

  2011cited by this paper
• RNA Interference and Cancer Therapy

  2011cited by this paper
• Protein transduction domain delivery of therapeutic macromolecules.

  2011cited by this paper
• Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor.

  2011cited by this paper
• Therapeutic delivery opportunities, obstacles and applications for cell-penetrating peptides.

  2011cited by this paper
• Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA.

  2011cited by this paper
• Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

  2011cited by this paper
• Click Chemistry with DNA

  2010cited by this paper
• Design of next-generation protein therapeutics.

  2010cited by this paper
• Endocytosis unplugged: multiple ways to enter the cell

  2010cited by this paper
• Development of DNA aptamers using Cell-SELEX

  2010cited by this paper
• Breaking down the barriers: siRNA delivery and endosome escape

  2010cited by this paper
• Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy.

  2010cited by this paper
• Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms.

  2010cited by this paper
• Aptamers as therapeutics

  2010cited by this paper
• Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.

  2010cited by this paper
• In situ visualization and dynamics of newly synthesized proteins in rat hippocampal neurons

  2010cited by this paper
• Aptamer-targeted cell-specific RNA interference

  2010cited by this paper
• Cell penetrating peptides: overview and applications to the delivery of oligonucleotides

  2010cited by this paper
• Click chemistry with DNA.

  2010cited by this paper
• Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates

  2010cited by this paper
• The Biological Effect of an Antisense Oligonucleotide Depends on Its Route of Endocytosis and Trafficking

  2010cited by this paper
• Off‐Target Effects Related to the Phosphorothioate Modification of Nucleic Acids

  2010cited by this paper
• Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor

  2010cited by this paper
• Recent developments in oligonucleotide conjugation.

  2010cited by this paper
• Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands.

  2010cited by this paper
• Chemical strategies for the synthesis of peptide-oligonucleotide conjugates.

  2010cited by this paper
• Rational design of cationic lipids for siRNA delivery

  2010cited by this paper
• 2′-O-Lysylaminohexyladenosine modified oligonucleotides

  2010cited by this paper
• Multivalent antibodies: when design surpasses evolution.

  2010cited by this paper
• RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.

  2010cited by this paper
• Oligonucleotide N3′→P5′ Phosphoramidates and Thio‐Phoshoramidates as Potential Therapeutic Agents

  2010cited by this paper
• A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.

  2009cited by this paper
• Chemical Modifications of Antisense Morpholino Oligomers Enhance Their Efficacy against Ebola Virus Infection

  2009cited by this paper
• Solid-phase synthesis of oligonucleotide conjugates useful for delivery and targeting of potential nucleic acid therapeutics.

  2009cited by this paper
• Mechanisms of endocytosis.

  2009cited by this paper
• Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology.

  2009cited by this paper
• Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents

  2009cited by this paper
• Targeted Delivery Systems for Oligonucleotide Therapeutics

  2009cited by this paper
• The chemical biology of aptamers.

  2009cited by this paper
• EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins

  2009cited by this paper
• Ligand‐Targeted Delivery of Small Interfering RNAs to Malignant Cells and Tissues

  2009cited by this paper
• PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma.

  2009cited by this paper
• Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN.

  2009cited by this paper
• Therapeutic Potential of Splice-Switching Oligonucleotides

  2009cited by this paper
• siRNA delivery using peptide transduction domains.

  2009cited by this paper
• Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors

  2009cited by this paper
• Revised Role of Glycosaminoglycans in TAT Protein Transduction Domain-mediated Cellular Transduction

  2009cited by this paper
• Gene Knockdowns in Adult Animals: PPMOs and Vivo-Morpholinos

  2009cited by this paper
• Oligonucleotide-polyamine conjugates: influence of length and position of 2'-attached polyamines on duplex stability and antisense effect.

  2009cited by this paper
• Single-cell identification in microbial communities by improved fluorescence in situ hybridization techniques

  2008cited by this paper
• Efficient In Vivo Delivery of siRNA to the Liver by Conjugation of α-Tocopherol.

  2008cited by this paper
• Twenty-five years of quantitative PCR for gene expression analysis.

  2008cited by this paper
• A combinatorial library of lipid-like materials for delivery of RNAi therapeutics

  2008cited by this paper
• Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases.

  2008cited by this paper
• Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA.

  2008cited by this paper
• Oligonucleotide-oligospermine conjugates (zip nucleic acids): a convenient means of finely tuning hybridization temperatures.

  2008cited by this paper
• Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis

  2008cited by this paper
• Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol.

  2008cited by this paper
• Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function

  2008cited by this paper
• Clinical experience with pegaptanib sodium

  2008cited by this paper
• Trivalent, Gal/GalNAc-containing ligands designed for the asialoglycoprotein receptor.

  2008cited by this paper

• Delivery strategies for RNA-targeting therapeutic nucleic acids and RNA-based vaccines against respiratory RNA viruses: IAV, SARS-CoV-2, RSV

  2025cites this paper
• RNA‐Based Therapeutics: Cutting‐Edge Advances in Clinical Research

  2025cites this paper
• Advanced site-specific analysis of insulin-PEG conjugates using MALDI-MS

  2025cites this paper
• Nanobody-Oligonucleotide Conjugates (NucleoBodies): The Next Frontier in Oligonucleotide Therapy

  2025cites this paper
• Novel Disulfide-Containing Linkages of Pyrimidine Nucleobases to Solid Supports: A Versatile Platform for Oligonucleotide Conjugation.

  2025cites this paper
• RNA-based antibacterial agents: Mechanisms, functional insights, and challenges in therapeutic development

  2025cites this paper
• Synthetic-polymer-assisted antisense oligonucleotide delivery: targeted approaches for precision disease treatment

  2025cites this paper
• Breaking the cellular delivery bottleneck: recent developments in direct cytosolic delivery of biologics

  2025cites this paper
• Activation of the coagulation cascade as a mechanism for selective nanoparticle-mediated RNA delivery to the endothelium in vivo

  2025cites this paper
• Functional bioconjugates for precision delivery of nucleic acid therapeutics

  2025cites this paper
• Thiol-Specific Linkers for the Synthesis of Oligonucleotide Conjugates via Metal-Free Thiol–Ene Click Reaction

  2024cites this paper
• Diastereomer Characterization of PS-Modified Synthetic Oligonucleotides Using Cyclic IMS-MS.

  2024cites this paper
• Gene editing of angiotensin for blood pressure management

  2024cites this paper
• In vitro screening of chemically synthesized dipeptide-antisense oligonucleotide conjugates to identify ligand molecules enhancing their activity.

  2024cites this paper
• Covalent Polymer‐RNA Conjugates for Potent Activation of the RIG‐I Pathway

  2024cites this paper
• Drug Metabolism Mechanisms And Pharmacokinetics Strategies In Implications For Drug Design: A Comprehensive Review

  2024cites this paper
• Enhanced Sequence-Specific DNA Recognition Using Oligodeoxynucleotide-Benzimidazole Conjugates

  2024cites this paper
• Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation

  2024cites this paper
• Isolectin B4 (IB4)-conjugated streptavidin for the selective knockdown of proteins in IB4-positive (+) nociceptors

  2024cites this paper
• Isolectin B4 (IB4)-conjugated streptavidin for the selective knockdown of proteins in IB4-positive (+) nociceptors

  2024cites this paper
• Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease.

  2024cites this paper
• Carrier systems of radiopharmaceuticals and the application in cancer therapy

  2024cites this paper
• Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach

  2024cites this paper
• Identification of cell type-specific cell-penetrating peptides through in vivo phage display leveraged by next generation sequencing.

  2024cites this paper
• Overview and Recent Advances in the Purification and Isolation of Therapeutic Oligonucleotides

  2024cites this paper
• Synthesis of peptide–siRNA conjugates via internal sulfonylphosphoramidate modifications and evaluation of their in vitro activity

  2023cites this paper
• Antisense oligonucleotide based therapeutics and its applications against bacterial infections

  2023cites this paper
• An insight of different classes of RNA-based therapeutic, nanodelivery and clinical status: current landscape

  2023cites this paper
• Fork- and Comb-like Lipophilic Structures: Different Chemical Approaches to the Synthesis of Oligonucleotides with Multiple Dodecyl Residues

  2023cites this paper
• A Pro-inflammatory Long Noncoding RNA Lncenc1 Regulates Inflammasome Activation in Macrophage.

  2023cites this paper
• Integration of functional peptides into nucleic acid-based nanostructures.

  2023cites this paper
• siRNA therapeutics: insights, challenges, remedies and future prospects

  2023cites this paper
• Therapeutic Oligonucleotides: An Outlook on Chemical Strategies to Improve Endosomal Trafficking

  2023cites this paper
• Convenient Solid-Phase Attachment of Small-Molecule Ligands to Oligonucleotides via a Biodegradable Acid-Labile P-N-Bond

  2023cites this paper
• Preparation of a Convertible Spacer Containing a Disulfide Group for Versatile Functionalization of Oligonucleotides

  2023cites this paper
• An Acid-Free Deprotection of 5′-Amino-Modified Oligonucleotides

  2023cites this paper
• Determination of Purge Factors for Use in Oligonucleotide Control Strategies

  2022cites this paper
• Exploring the Structural Diversity of DNA Bottlebrush Polymers Using an Oligonucleotide Macromonomer Approach.

  2022cites this paper
• Synthesis of a Convertible Linker Containing a Disulfide Group for Oligonucleotide Functionalization.

  2022cites this paper
• RNA-based therapeutics: an overview and prospectus

  2022cites this paper
• Programmable self-regulated molecular buffers for precise sustained drug delivery

  2022cites this paper
• Reality check: lipid-oligonucleotide conjugates for therapeutic applications

  2022cites this paper
• Preparation of Folic Acid Conjugated Oligonucleotide

  2021cites this paper
• Green synthesis of phosphoramidates and evaluation of their α-amylase activity by in silico and in vitro studies

  2021cites this paper
• Purification of N-acetylgalactosamine-modified-oligonucleotides using orthogonal anion-exchange and mixed-mode chromatography approaches.

  2021cites this paper
• Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics.

  2021cites this paper
• Oligonucleotides Containing 1-Aminomethyl or 1-Mercaptomethyl-2-deoxy-d-ribofuranoses: Synthesis, Purification, Characterization, and Conjugation with Fluorophores and Lipids

  2021cites this paper
• Disulfide Bridging Strategies in Viral and Nonviral Platforms for Nucleic Acid Delivery.

  2021cites this paper
• A Versatile Solid-Phase Approach to the Synthesis of Oligonucleotide Conjugates with Biodegradable Hydrazone Linker

  2021cites this paper
• Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates

  2021cites this paper
• Lymphocyte Disturbance in The [Asp521Asn] ZAP70 Mutation and An Overview of All Phenotype/Genotype

  2021cites this paper
• SeqStain is an efficient method for multiplexed, spatialomic profiling of human and murine tissues

  2021cites this paper
• Access to 1'-Amino Carbocyclic Phosphoramidite to Enable Postsynthetic Functionalization of Oligonucleotides.

  2021cites this paper
• Synthetic Technology of Noncoding RNAs Used in Bone Disease Research and Therapeutics

  2021cites this paper
• Therapeutic strategies for modulating epigenetic mechanisms in cardiovascular disease

  2021cites this paper
• Synthetic Approaches for Copolymers Containing Nucleic Acids and Analogues: Challenges and Opportunities.

  2021cites this paper
• Phosphorothioate modified oligonucleotide–protein interactions

  2020cites this paper
• Association of miR-760 with cancer: an overview.

  2020cites this paper
• SeqStain using fluorescent-DNA conjugated antibodies allows efficient, multiplexed, spatialomic profiling of human and murine tissues

  2020cites this paper
• Gallium-68 radiolabeling of biomolecules for positron emission tomography with special reference to imaging of inflammation and bone

  2020influential citation
• Noncationic Material Design for Nucleic Acid Delivery

  2020cites this paper
• Effect of inclisiran, the siRNA against PCSK9, on platelets, immune cells and immunological biomarkers - a pre-specified analysis from ORION-1.

  2020cites this paper
• Paving the Road for RNA Therapeutics

  2020cites this paper
• Challenges in Oligonucleotide Therapeutics

  2020cites this paper
• Aptamer and Riboswitches: A Novel Tool for the Need of New Antimicrobial Active Compounds

  2020cites this paper
• Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules

  2020cites this paper
• Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with Trastuzumab: A Proof-of-Concept Study in Prostate Cancer

  2020cites this paper
• Acid Gapmers and Conjugates Potently Silence ADAM 33 , an Asthma-Associated Metalloprotease with Nuclear-Localized mRNA

  2019cites this paper
• RNA therapy: Are we using the right molecules?

  2019influential citation
• Antitumor effect of palmitic acid‐conjugated DsiRNA for colon cancer in a mouse subcutaneous tumor model

  2019cites this paper
• Thiol-Cyanobenzothiazole Ligation for the Efficient Preparation of Peptide-PNA Conjugates.

  2019cites this paper
• Covalent Fluorophore Labeling of Oligonucleotides and Generation of Other Oligonucleotide Bioconjugates.

  2019cites this paper
• Self-Assembly of DNA-Containing Copolymers.

  2019cites this paper
• Quantification of siRNA-Antibody Conjugates in Biological Matrices by Triplex-Forming Oligonucleotide ELISA

  2019cites this paper
• Expanding the materials space of DNA via organic-phase ring-opening metathesis polymerization.

  2019cites this paper
• Targeted delivery and endosomal cellular uptake of DARPin-siRNA bioconjugates: Influence of linker stability on gene silencing.

  2019cites this paper
• Disulfide bridge as a linker in nucleic acids' bioconjugation. Part I: An overview of synthetic strategies.

  2019cites this paper
• Lipid-based Vehicles for siRNA Delivery in Biomedical Field.

  2019cites this paper
• THERAPEUTIC OLIGONUCLEOTIDES, IMPURITIES, DEGRADANTS, AND THEIR CHARACTERIZATION BY MASS SPECTROMETRY.

  2019cites this paper
• Disulfide bridge as a linker in nucleic acids' bioconjugation. Part II: A summary of practical applications.

  2019cites this paper
• Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.

  2018cites this paper
• Development of Protecting Groups for Prodrug-Type Oligonucleotide Medicines.

  2018cites this paper
• Extrahepatic Targeting of Oligonucleotides with Receptor-Binding Non-Immunoglobulin Scaffold Proteins

  2018cites this paper
• Reaction-Mediated Desorption of Macromolecules: Novel Phenomenon Enabling Simultaneous Reaction and Separation.

  2018cites this paper
• Tissue Distribution, Metabolism, and Clearance

  2018cites this paper
• A convenient solid phase approach to obtain lipophilic 5′-phosphoramidate derivatives of DNA and RNA oligonucleotides

  2018cites this paper
• Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development.

  2018cites this paper
• Development of stable liquid formulations for oligonucleotides

  2018cites this paper
• A General Overview on Non-coding RNA-Based Diagnostic and Therapeutic Approaches for Liver Diseases

  2018cites this paper
• Synthesis of Lipid-Carbohydrate-Peptidyl-RNA Conjugates to Explore the Limits Imposed by the Substrate Specificity of Cell Wall Enzymes on the Acquisition of Drug Resistance.

  2018cites this paper
• Synthesis and biophysical properties of 5'-thio-2',4'-BNA/LNA oligonucleotide.

  2018cites this paper
• Conjugatable and Bioreduction Cleavable Linker for the 5'-Functionalization of Oligonucleotides.

  2017cites this paper
• Lipid‐oligonucleotide conjugates improve cellular uptake and efficiency of TCTP‐antisense in castration‐resistant prostate cancer

  2017cites this paper
• Long‐term regulation of gene expression in muscle cells by systemically delivered siRNA

  2017cites this paper
• Amphiphilic lipopeptide significantly enhances uptake of charge-neutral splice switching morpholino oligonucleotide in spinal muscular atrophy patient-derived fibroblasts.

  2017cites this paper
• Locked Nucleic Acid Gapmers and Conjugates Potently Silence ADAM33, an Asthma-Associated Metalloprotease with Nuclear-Localized mRNA

  2017cites this paper
• Ablation of Hepatic Production of the Acid-Labile Subunit in Bovine-GH Transgenic Mice: Effects on Organ and Skeletal Growth

  2017cites this paper
• Locked Nucleic Acid gapmers and conjugates induce potent silencing of ADAM 33 , an asthma-associated metalloprotease with nuclear-localized mRNA

  2017cites this paper
• RNAi-Mediated Knockdown of Protein Expression.

  2017cites this paper
• Design, Preparation and Characterization of Modular Squalene-based Nanosystems for Controlled Drug Release.

  2017cites this paper